The ISAR-REACT 5 (Intracoronary Stenting and Antithrombotic Regimen 5) trial presented at the European Society of Cardiology Congress 2019 showed prasugrel had significantly lower major adverse cardiovascular events compared with ticagrelor in patients undergoing percutaneous coronary intervention (PCI).

Keywords: Acute Coronary Syndrome, Anticoagulants, Coronary Angiography, Angiography, Percutaneous Coronary Intervention, Stents, ESC 19, ESC Congress

< Back to Listings